depart ceo posit growth
miss consensu revenu extraordinari item seem issu
place historical/industri context compani organ growth
extraordinari retir ceo rob friel step role year ago
struggl achiev industri growth would complet whif
result macroeconom environ like today shift mix
china/asia exposur increas diagnost exposur growth technolog
analyt instrument posit compani visibl growth ahead
maintain neutral rate
post report organ growth versu street estim
janney ep versu guidance/street estim
diagnost miss mn quarter report organ
street estim due facil consolid genom servic consolid
lab pittsburgh lead backlog build lighter revenu discoveri
analyt miss mn industri market signific part
busi growth improv compar organ
academ govern improv appli market remain soft
despit time macro headwind continu execut margin
expans initi quarter gross margin expand bp
oper margin opm expand bp addit
manag rais opm expans guidanc top end initi
manag tweak guidanc slightli bn revenu
rais ep guid top end initi rang
manag provid guidanc revenu organ
ep
maintain neutral rate fv fv reach
appli multipl consolid ep
subtract net debt fv also reach appli
multipl ebitda subtract net debt compar
peer trade ep ebitda estim
million except per share data
euroimmun inc dx
amort intang
annual revenu break-out margin
revenu
total sale
revenu
